Evidence map›Paper›PMID 29696459›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2018

Economic evaluation of Zepatier for the management of HCV in the Italian scenario.

F R Rolli, M Ruggeri, F Kheiraoui, C Drago, M Basile, C Favaretti, A Cicchetti

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

F R RolliCatholic University of Sacred Heart, Largo Francesco Vito 1, 00186, Rome, Italy.
M RuggeriCatholic University of Sacred Heart, Largo Francesco Vito 1, 00186, Rome, Italy.
F KheiraouiIstituto di Sanità Pubblica, Sezione Igiene, Catholic University of Sacred Heart, Rome, Italy.
C Drago"Nicolò Cusano" University, Rome, Italy.
M BasileCatholic University of Sacred Heart, Largo Francesco Vito 1, 00186, Rome, Italy. michele.basile@unicatt.it.
C FavarettiVIHTALI, Value in Health Technology and Academy for Leadership and Innovation Spin-Off of the Catholic University of Sacred Heart, Rome, Italy.
A CicchettiCatholic University of Sacred Heart, Largo Francesco Vito 1, 00186, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) is a major health issue worldwide. New generation of direct-active antiviral medications is an epoch-making turning point in the management of HCV infections.

objectiveConducing a cost-effectiveness analysis comparing the combination of elbasvir/grazoprevir and sofosbuvir + pegylated interferon/ribavirin for the management of all HCV patients (even those in the initial stages of fibrosis).

methodsA Markov model was built on the natural history of the disease to assess the efficacy of the alternatives. The outcomes are expressed in terms of quality adjusted life-years (QALYs) and result in terms of incremental cost-effectiveness ratio).

resultsElbasvir/grazoprevir implies an expenditure of €21,104,253.74 with a gain of 19,287.90 QALYs and sofosbuvir + pegylated interferon/ribavirin implies an expenditure of €31,904,410.11 with a gain of 18,855.96 QALYs. Elbasvir/grazoprevir is thus a dominant strategy.

conclusionConsideration should be given to the opportunity cost of not treating patients with a lower degree of fibrosis (F0-F2).

Indexed as

Antiviral AgentsBenzofuransCost-Benefit AnalysisCost of IllnessDrug CombinationsHepacivirusHepatitis CHumansImidazolesInterferonsItalyMarkov ChainsQuality-Adjusted Life YearsQuinoxalinesRibavirinSofosbuvirAntiviral AgentsBenzofuransDrug Combinationselbasvir-grazoprevir drug combinationImidazolesInterferonsQuinoxalinesRibavirinSofosbuvirCost-effectiveness analysisHCVICEROpportunity costSensitivity analysis

Identifiers

PMID29696459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.